IFLR1000

Gilead Sciences $11.9 billion acquisition of Kite Pharma

28/8/2017
Public acquisition
Select tab

$ 11.9 billion

Announced

28/8/2017

Overview:

  • Gilead Sciences has acquired Kite Pharma for $11.9 billion.
  • Gilead will pay $180 per share in an all-cash deal.
  • The growth of Gilead has been based on hepatitis C drugs, but recently sales have been decreasing.
  • Bank of America Merrill Lynch and Lazard were Gilead’s financial advisers, while Centerview Partners advised Kite.

 Katrin Kostadinova - Data analyst

Jurisdiction:

United States

Deal type:

Public acquisition

Practice area:

M&A

Governing law:

United States

Industry sector:

Pharmaceuticals and life sciences

Firms:
Cooley

Party: Kite Pharma (Target)

Skadden Arps Slate Meagher & Flom

Party: Gilead Sciences (Acquirer)

Sullivan & Cromwell

Party: Kite Pharma (Target)

Lawyers: Alison Ressler, Eric Krautheimer, Matthew Friestedt, Nader Mousavi

Related deals